You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDopamine
Accession NumberDB00988  (APRD00085)
TypeSmall Molecule
GroupsApproved
Description

One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action. [PubChem]

Structure
Thumb
Synonyms
2-(3,4-Dihydroxyphenyl)ethylamine
3-Hydroxytyramine
3,4-Dihydroxyphenethylamine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
Deoxyepinephrine
Dopamin
Dopamina
Dopamine
Dopaminum
Dophamine
Hydroxytyramin
Hydroxytyramine
Oxytyramine
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dopamine HCl Inj 4%liquid40 mgintravenousInternational Medication Systems Ltd.1980-12-311997-08-15Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dopamine Hydrochlorideinjection, solution, concentrate40 mg/mLintravenousREMEDYREPACK INC.2015-01-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dopamine Hydrochlorideinjection, solution, concentrate40 mg/mLintravenousHospira, Inc.1981-05-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dopamine Hydrochlorideinjection, solution, concentrate40 mg/mLintravenousCardinal Health1981-05-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dopamine Hydrochlorideinjection, solution, concentrate80 mg/mLintravenousHospira, Inc.1981-05-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dopamine Hydrochlorideinjection40 mg/mLintravenousGENERAL INJECTABLES AND VACCINES, INC.2015-09-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dopamine Hydrochlorideinjection40 mg/mLintravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dopamine Hydrochlorideinjection, solution, concentrate40 mg/mLintravenousHospira, Inc.1981-05-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dopamine Hydrochloride and Dextroseinjection, solution80 mg/100mLintravenousBaxter Healthcare Corporation1987-03-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dopamine Hydrochloride and Dextroseinjection, solution1.6 mg/mLintravenousHospira, Inc.1983-09-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dopamine Hydrochloride and Dextroseinjection, solution.8 mg/mLintravenousHospira, Inc.1983-09-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dopamine Hydrochloride and Dextroseinjection, solution160 mg/100mLintravenousHospira, Inc.1981-05-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dopamine Hydrochloride and Dextroseinjection, solution320 mg/100mLintravenousBaxter Healthcare Corporation1987-03-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dopamine Hydrochloride and Dextroseinjection, solution160 mg/100mLintravenousBaxter Healthcare Corporation1987-03-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dopamine Hydrochloride and Dextroseinjection, solution3.2 mg/mLintravenousHospira, Inc.1983-09-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Intropin Injection 40mg/mlsolution40 mgintravenousBristol Myers Squibb Canada1993-12-312006-05-29Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dopamineinjection, solution80 mg/mLintravenousGeneral Injectables & Vaccines, Inc2010-04-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dopamine HClinjection, solution160 mg/mLintravenousAmerican Regent, Inc.1990-09-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dopamine HClinjection, solution40 mg/mLintravenousCardinal Health1987-02-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dopamine HClinjection, solution80 mg/mLintravenousCardinal Health1990-09-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dopamine HClinjection, solution80 mg/mLintravenousAmerican Regent, Inc.1990-09-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dopamine HClinjection, solution40 mg/mLintravenousAmerican Regent, Inc.1990-09-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dopamine Hydrochlorideinjection, solution40 mg/mLintravenousGeneral Injectables & Vaccines, Inc2010-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
IntropinNot Available
RevimineNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Dopamine Hydrochloride
Thumb
  • InChI Key: CTENFNNZBMHDDG-UHFFFAOYSA-N
  • Monoisotopic Mass: 189.05565634
  • Average Mass: 189.639
DBSALT000508
Categories
CAS number51-61-6
WeightAverage: 153.1784
Monoisotopic: 153.078978601
Chemical FormulaC8H11NO2
InChI KeyInChIKey=VYFYYTLLBUKUHU-UHFFFAOYSA-N
InChI
InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2
IUPAC Name
4-(2-aminoethyl)benzene-1,2-diol
SMILES
NCCC1=CC(O)=C(O)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as catecholamines and derivatives. These are compounds containing 4-(2-Aminoethyl)pyrocatechol [4-(2-aminoethyl)benzene-1,2-diol] or a derivative thereof formed by substitution.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenols and derivatives
Direct ParentCatecholamines and derivatives
Alternative Parents
Substituents
  • Catecholamine
  • Phenethylamine
  • Aralkylamine
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure
PharmacodynamicsDopamine is a natural catecholamine formed by the decarboxylation of 3,4-dihydroxyphenylalanine (DOPA). It is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system, especially in the nigrostriatal tract, and in a few peripheral sympathetic nerves. Dopamine produces positive chronotropic and inotropic effects on the myocardium, resulting in increased heart rate and cardiac contractility. This is accomplished directly by exerting an agonist action on beta-adrenoceptors and indirectly by causing release of norepinephrine from storage sites in sympathetic nerve endings.
Mechanism of actionDopamine is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system. Dopamine produces positive chronotropic and inotropic effects on the myocardium, resulting in increased heart rate and cardiac contractility. This is accomplished directly by exerting an agonist action on beta-adrenoceptors and indirectly by causing release of norepinephrine from storage sites in sympathetic nerve endings. In the brain, dopamine actas as an agonist to the five dopamine receptor subtypes (D!, D2, D3, D4, D5).
AbsorptionDopamine is rapidly absorbed from the small intestine.
Volume of distributionNot Available
Protein bindingNo information currently available on protein binding.
Metabolism

Biotransformation of dopamine proceeds rapidly to yield the principal excretion products, 3-4-dihydroxy-phenylacetic acid (DOPAC) and 3-methoxy-4-hydroxy-phenylacetic acid (homovanillic acid, HVA).

SubstrateEnzymesProduct
Dopamine
Not Available
6-HydroxydopamineDetails
Dopamine
Not Available
Dopamine 4-sulfateDetails
Dopamine
Not Available
Dopamine 3-O-sulfateDetails
Dopamine
Not Available
Dopamine glucuronideDetails
Dopamine
Not Available
Dopamine quinoneDetails
Route of eliminationIt has been reported that about 80% of the drug is excreted in the urine within 24 hours, primarily as HVA and its sulfate and glucuronide conjugates and as 3,4-dihydroxyphenylacetic acid. A very small portion is excreted unchanged.
Half life2 minutes
ClearanceNot Available
ToxicityLD50 oral mice = 1460 mg/kg, LD50 oral rats = 1780 mg/kg. Spasm or closing of eyelids, nausea, vomiting, cardiac arrhythmias, involuntary movements of the body including the face, tongue, arms, hand, head, and upper body; hypotension, haemolytic anaemia, urinary retention, duodenal ulcer, sialorrhea, ataxia, abdominal pain, dry mouth, nightmares, tachypnoea, bruxism, confusion, and insomnia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9547
Blood Brain Barrier-0.8414
Caco-2 permeable-0.5479
P-glycoprotein substrateNon-substrate0.5431
P-glycoprotein inhibitor INon-inhibitor0.9739
P-glycoprotein inhibitor IINon-inhibitor0.9357
Renal organic cation transporterNon-inhibitor0.7115
CYP450 2C9 substrateNon-substrate0.8462
CYP450 2D6 substrateNon-substrate0.6383
CYP450 3A4 substrateNon-substrate0.6905
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9459
CYP450 2D6 inhibitorNon-inhibitor0.9422
CYP450 2C19 inhibitorNon-inhibitor0.9477
CYP450 3A4 inhibitorNon-inhibitor0.9001
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8648
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.8642
BiodegradationReady biodegradable0.7449
Rat acute toxicity2.1415 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7712
hERG inhibition (predictor II)Non-inhibitor0.5715
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Abbott laboratories hosp products div
  • Abraxis pharmaceutical products
  • Astrazeneca lp
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • International medication system
  • Luitpold pharmaceuticals inc
  • Smith and nephew solopak div smith and nephew
  • Teva parenteral medicines inc
  • Warner chilcott div warner lambert co
  • B braun medical inc
  • Baxter healthcare corp
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintravenous160 mg/mL
Injection, solutionintravenous40 mg/mL
Injection, solutionintravenous80 mg/mL
Liquidintravenous40 mg
Injectionintravenous40 mg/mL
Injection, solution, concentrateintravenous40 mg/mL
Injection, solution, concentrateintravenous80 mg/mL
Injection, solutionintravenous.8 mg/mL
Injection, solutionintravenous1.6 mg/mL
Injection, solutionintravenous160 mg/100mL
Injection, solutionintravenous3.2 mg/mL
Injection, solutionintravenous320 mg/100mL
Injection, solutionintravenous80 mg/100mL
Solutionintravenous40 mg
Prices
Unit descriptionCostUnit
Dopamine 40 mg/ml vial0.15USD ml
Dopamine 800 mg-d5w 500 ml0.05USD ml
Dopamine 400 mg-d5w 250 ml0.04USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point128 °CPhysProp
boiling point227 °C at 2.30E+01 mm HgPhysProp
water solubility600 g/LNot Available
logP-0.98HANSCH,C ET AL. (1995)
Caco2 permeability-5.03ADME Research, USCD
pKa8.93PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
Water Solubility7.43 mg/mLALOGPS
logP-0.4ALOGPS
logP0.03ChemAxon
logS-1.3ALOGPS
pKa (Strongest Acidic)10.01ChemAxon
pKa (Strongest Basic)9.27ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area66.48 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity43.25 m3·mol-1ChemAxon
Polarizability16.21 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)splash10-5z10000000-117a1a7207245f5377e7View in MoNA
GC-MSGC-MS Spectrum - GC-MS (4 TMS)splash10-7z20000000-8b7dcae82868308513daView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-gz00000000-ff51177ebcb89b8c956cView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-z700000000-a554eb700a06cecb8292View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-z100000000-db9813e1025f237a549bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Negativesplash10-0z00000000-27e0d71db6d14d79759cView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Negativesplash10-0z00000000-f1cf97c0d0dd509e229eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Negativesplash10-0z00000000-aa09a2411e287abe74edView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Negativesplash10-6z00000000-97c42b109cab2005373dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Negativesplash10-zr00000000-974bd18febffcceea2d6View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Positivesplash10-0z00000000-099173d4201beca9e548View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Positivesplash10-6z00000000-9dc09f2661247c9d84b0View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Positivesplash10-zc00000000-8b85fa9aac1ffb4c2873View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Positivesplash10-z100000000-9ea16d2057010279d433View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Positivesplash10-z000000000-32ca2db8fe2b4729ab94View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Positivesplash10-0z00000000-ff587935c79b4592ffcfView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Positivesplash10-5z00000000-8a35d8a2241bc18d6c50View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Positivesplash10-zd00000000-356a4b8f268863c7893eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Positivesplash10-z100000000-a88c1004f357858fbc6cView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Positivesplash10-z000000000-271874005dcb90288512View in MoNA
MSMass Spectrum (Electron Ionization)splash10-wz00000000-88acdc978fe4a64e0fc5View in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Klaus Schoellkopf, Rudolf Albrecht, Manfred Lehmann, Gertrud Schroeder, “Novel dopamine derivatives, processes for their preparation, and their use as medicinal agents.” U.S. Patent US4958026, issued February, 1972.

US4958026
General References
  1. Barron AB, Maleszka R, Vander Meer RK, Robinson GE: Octopamine modulates honey bee dance behavior. Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1703-7. Epub 2007 Jan 19. Pubmed
  2. Giuliano F, Allard J: Dopamine and male sexual function. Eur Urol. 2001 Dec;40(6):601-8. Pubmed
  3. Giuliano F, Allard J: Dopamine and sexual function. Int J Impot Res. 2001 Aug;13 Suppl 3:S18-28. Pubmed
  4. Berridge KC, Robinson TE: What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev. 1998 Dec;28(3):309-69. Pubmed
  5. Pecina S, Cagniard B, Berridge KC, Aldridge JW, Zhuang X: Hyperdopaminergic mutant mice have higher “wanting” but not “liking” for sweet rewards. J Neurosci. 2003 Oct 15;23(28):9395-402. Pubmed
External Links
ATC CodesC01CA04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (72.1 KB)
Interactions
Drug Interactions
Drug
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Dopamine.
AcetaminophenThe risk or severity of adverse effects can be increased when Dopamine is combined with Acetaminophen.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Dopamine is combined with Acetylsalicylic acid.
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Dopamine.
AminophyllineThe risk or severity of adverse effects can be increased when Dopamine is combined with Aminophylline.
AmitriptylineAmitriptyline may increase the activities of Dopamine.
AmphetamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Amphetamine.
ArformoterolThe risk or severity of adverse effects can be increased when Dopamine is combined with Arformoterol.
ArmodafinilThe risk or severity of adverse effects can be increased when Dopamine is combined with Armodafinil.
ArticaineThe risk or severity of adverse effects can be increased when Dopamine is combined with Articaine.
AtomoxetineAtomoxetine may increase the hypertensive activities of Dopamine.
BenzphetamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Benzphetamine.
Benzylpenicilloyl PolylysineDopamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BupropionThe serum concentration of Dopamine can be increased when it is combined with Bupropion.
ButalbitalThe risk or severity of adverse effects can be increased when Dopamine is combined with Butalbital.
CabergolineCabergoline may increase the hypertensive activities of Dopamine.
CaffeineThe risk or severity of adverse effects can be increased when Dopamine is combined with Caffeine.
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Dopamine.
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Dopamine.
CocaineThe risk or severity of adverse effects can be increased when Dopamine is combined with Cocaine.
DesfluraneDesflurane may increase the arrhythmogenic activities of Dopamine.
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dopamine is combined with Dexmethylphenidate.
DextroamphetamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Dextroamphetamine.
DiethylpropionThe risk or severity of adverse effects can be increased when Dopamine is combined with Diethylpropion.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dopamine is combined with Dihydrocodeine.
DipivefrinThe risk or severity of adverse effects can be increased when Dopamine is combined with Dipivefrin.
DobutamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Dobutamine.
DoxapramThe risk or severity of adverse effects can be increased when Dopamine is combined with Doxapram.
DoxofyllineThe risk or severity of adverse effects can be increased when Dopamine is combined with Doxofylline.
DronabinolDronabinol may increase the tachycardic activities of Dopamine.
DyphyllineThe risk or severity of adverse effects can be increased when Dopamine is combined with Dyphylline.
EphedrineThe risk or severity of adverse effects can be increased when Dopamine is combined with Ephedrine.
EpinephrineThe risk or severity of adverse effects can be increased when Dopamine is combined with Epinephrine.
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Dopamine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Dopamine is combined with Fluticasone Propionate.
FormoterolThe risk or severity of adverse effects can be increased when Dopamine is combined with Formoterol.
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dopamine.
IndacaterolThe risk or severity of adverse effects can be increased when Dopamine is combined with Indacaterol.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Dopamine.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Dopamine is combined with Ipratropium bromide.
IsofluraneIsoflurane may increase the arrhythmogenic activities of Dopamine.
IsomethepteneThe risk or severity of adverse effects can be increased when Dopamine is combined with Isometheptene.
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Dopamine.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Dopamine.
LevonordefrinThe risk or severity of adverse effects can be increased when Dopamine is combined with Levonordefrin.
LinezolidLinezolid may increase the hypertensive activities of Dopamine.
LisdexamfetamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Lisdexamfetamine.
LurasidoneDopamine may increase the hypotensive activities of Lurasidone.
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Dopamine.
MepivacaineThe risk or severity of adverse effects can be increased when Dopamine is combined with Mepivacaine.
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Dopamine.
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Dopamine.
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Dopamine.
MethylphenidateThe risk or severity of adverse effects can be increased when Dopamine is combined with Methylphenidate.
MidodrineThe risk or severity of adverse effects can be increased when Dopamine is combined with Midodrine.
ModafinilThe risk or severity of adverse effects can be increased when Dopamine is combined with Modafinil.
NabiloneNabilone may increase the tachycardic activities of Dopamine.
NadololNadolol may increase the activities of Dopamine.
NaphazolineThe risk or severity of adverse effects can be increased when Naphazoline is combined with Dopamine.
NorepinephrineThe risk or severity of adverse effects can be increased when Dopamine is combined with Norepinephrine.
OlodaterolThe risk or severity of adverse effects can be increased when Dopamine is combined with Olodaterol.
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Dopamine.
OxymetazolineThe risk or severity of adverse effects can be increased when Dopamine is combined with Oxymetazoline.
PhendimetrazineThe risk or severity of adverse effects can be increased when Dopamine is combined with Phendimetrazine.
PheniramineThe risk or severity of adverse effects can be increased when Dopamine is combined with Pheniramine.
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Dopamine.
PhentermineThe risk or severity of adverse effects can be increased when Dopamine is combined with Phentermine.
PhenylephrineThe risk or severity of adverse effects can be increased when Dopamine is combined with Phenylephrine.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Dopamine.
PirbuterolThe risk or severity of adverse effects can be increased when Dopamine is combined with Pirbuterol.
PrazosinPrazosin may decrease the vasoconstricting activities of Dopamine.
PropylhexedrineThe risk or severity of adverse effects can be increased when Dopamine is combined with Propylhexedrine.
PseudoephedrineThe risk or severity of adverse effects can be increased when Dopamine is combined with Pseudoephedrine.
RacepinephrineThe risk or severity of adverse effects can be increased when Dopamine is combined with Racepinephrine.
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Dopamine.
SalbutamolThe risk or severity of adverse effects can be increased when Dopamine is combined with Salbutamol.
SalmeterolThe risk or severity of adverse effects can be increased when Dopamine is combined with Salmeterol.
SevofluraneSevoflurane may increase the arrhythmogenic activities of Dopamine.
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Dopamine.
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Dopamine.
TerbutalineThe risk or severity of adverse effects can be increased when Dopamine is combined with Terbutaline.
TheophyllineThe risk or severity of adverse effects can be increased when Dopamine is combined with Theophylline.
TolcaponeThe metabolism of Dopamine can be decreased when combined with Tolcapone.
TriprolidineThe risk or severity of adverse effects can be increased when Dopamine is combined with Triprolidine.
VenlafaxineVenlafaxine may increase the tachycardic activities of Dopamine.
VilanterolThe risk or severity of adverse effects can be increased when Dopamine is combined with Vilanterol.
Food InteractionsNot Available

Targets

1. D(2) dopamine receptor

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
D(2) dopamine receptor P14416 Details

References:

  1. Ostadali MR, Ahangari G, Eslami MB, Razavi A, Zarrindast MR, Ahmadkhaniha HR, Boulhari J: The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74. Pubmed
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. D(1A) dopamine receptor

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
D(1A) dopamine receptor P21728 Details

References:

  1. Ostadali MR, Ahangari G, Eslami MB, Razavi A, Zarrindast MR, Ahmadkhaniha HR, Boulhari J: The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74. Pubmed
  2. Dolzan V, Plesnicar BK, Serretti A, Mandelli L, Zalar B, Koprivsek J, Breskvar K: Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. Am J Med Genet B Neuropsychiatr Genet. 2007 Sep 5;144(6):809-15. Pubmed
  3. Hoenicka J, Aragues M, Ponce G, Rodriguez-Jimenez R, Jimenez-Arriero MA, Palomo T: From dopaminergic genes to psychiatric disorders. Neurotox Res. 2007 Jan;11(1):61-72. Pubmed
  4. da Silva Lobo DS, Vallada HP, Knight J, Martins SS, Tavares H, Gentil V, Kennedy JL: Dopamine genes and pathological gambling in discordant sib-pairs. J Gambl Stud. 2007 Dec;23(4):421-33. Epub 2007 Mar 30. Pubmed
  5. Fu W, Shen J, Luo X, Zhu W, Cheng J, Yu K, Briggs JM, Jin G, Chen K, Jiang H: Dopamine D1 receptor agonist and D2 receptor antagonist effects of the natural product (-)-stepholidine: molecular modeling and dynamics simulations. Biophys J. 2007 Sep 1;93(5):1431-41. Epub 2007 Apr 27. Pubmed

3. D(1B) dopamine receptor

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
D(1B) dopamine receptor P21918 Details

References:

  1. Ostadali MR, Ahangari G, Eslami MB, Razavi A, Zarrindast MR, Ahmadkhaniha HR, Boulhari J: The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74. Pubmed

4. D(3) dopamine receptor

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
D(3) dopamine receptor P35462 Details

References:

  1. Ostadali MR, Ahangari G, Eslami MB, Razavi A, Zarrindast MR, Ahmadkhaniha HR, Boulhari J: The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74. Pubmed

5. D(4) dopamine receptor

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
D(4) dopamine receptor P21917 Details

References:

  1. Ostadali MR, Ahangari G, Eslami MB, Razavi A, Zarrindast MR, Ahmadkhaniha HR, Boulhari J: The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74. Pubmed

6. Sodium-dependent dopamine transporter

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inducer

Components

Name UniProt ID Details
Sodium-dependent dopamine transporter Q01959 Details

References:

  1. Ostadali MR, Ahangari G, Eslami MB, Razavi A, Zarrindast MR, Ahmadkhaniha HR, Boulhari J: The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74. Pubmed

7. Dopamine beta-hydroxylase

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: ligand

Components

Name UniProt ID Details
Dopamine beta-hydroxylase P09172 Details

References:

  1. Goldman JM, Cooper RL, Murr AS: Reproductive functions and hypothalamic catecholamines in response to the soil fumigant metam sodium: adaptations to extended exposures. Neurotoxicol Teratol. 2007 May-Jun;29(3):368-76. Epub 2006 Dec 6. Pubmed
  2. Arboleda G, Huang TJ, Waters C, Verkhratsky A, Fernyhough P, Gibson RM: Insulin-like growth factor-1-dependent maintenance of neuronal metabolism through the phosphatidylinositol 3-kinase-Akt pathway is inhibited by C2-ceramide in CAD cells. Eur J Neurosci. 2007 May;25(10):3030-8. Pubmed
  3. Garland EM, Black BK, Harris PA, Robertson D: Dopamine-beta-hydroxylase in postural tachycardia syndrome. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H684-90. Pubmed
  4. Pyatskowit JW, Prohaska JR: Rodent brain and heart catecholamine levels are altered by different models of copper deficiency. Comp Biochem Physiol C Toxicol Pharmacol. 2007 Mar;145(2):275-81. Epub 2007 Jan 12. Pubmed
  5. LeBlanc J, Ducharme MB: Plasma dopamine and noradrenaline variations in response to stress. Physiol Behav. 2007 Jun 8;91(2-3):208-11. Epub 2007 Mar 2. Pubmed

8. 5-hydroxytryptamine receptor 1A

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 1A P08908 Details

References:

  1. Weber JT, Hayataka K, O’Connor MF, Parker KK: Rabbit cerebral cortex 5HT1a receptors. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1997 May;117(1):19-24. Pubmed
  2. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O’Brien A, White A, Kennedy JM, Craymer K, Farrington L, Auh JS: Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr. 1998 Mar;178:440-66. Pubmed

9. 5-hydroxytryptamine receptor 7

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 7 P34969 Details

References:

  1. Lovenberg TW, Baron BM, de Lecea L, Miller JD, Prosser RA, Rea MA, Foye PE, Racke M, Slone AL, Siegel BW, et al.: A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron. 1993 Sep;11(3):449-58. Pubmed
  2. Shen Y, Monsma FJ Jr, Metcalf MA, Jose PA, Hamblin MW, Sibley DR: Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem. 1993 Aug 25;268(24):18200-4. Pubmed

10. D(1) dopamine receptor

Kind: Protein group

Organism: Human

Pharmacological action: unknown

Actions: agonist

Components

Name UniProt ID Details
D(1A) dopamine receptor P21728 Details
D(1B) dopamine receptor P21918 Details

References:

  1. Hubner H, Haubmann C, Utz W, Gmeiner P: Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonists recognizing preferentially the D(3) subtype. J Med Chem. 2000 Feb 24;43(4):756-62. Pubmed

11. Sodium-dependent noradrenaline transporter

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Sodium-dependent noradrenaline transporter P23975 Details

References:

  1. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS: Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001 Jan;39(1):32-41. Pubmed

12. Sodium-dependent serotonin transporter

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Sodium-dependent serotonin transporter P31645 Details

References:

  1. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS: Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001 Jan;39(1):32-41. Pubmed

Enzymes

1. Amine oxidase [flavin-containing] A

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Amine oxidase [flavin-containing] A P21397 Details

References:

  1. Bortolato M, Chen K, Shih JC: Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1527-33. Epub 2008 Jul 4. Pubmed
  2. Kaludercic N, Carpi A, Menabo R, Di Lisa F, Paolocci N: Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim Biophys Acta. 2011 Jul;1813(7):1323-32. Epub 2010 Sep 24. Pubmed
  3. Volavka J, Bilder R, Nolan K: Catecholamines and aggression: the role of COMT and MAO polymorphisms. Ann N Y Acad Sci. 2004 Dec;1036:393-8. Pubmed

2. Amine oxidase [flavin-containing] B

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Amine oxidase [flavin-containing] B P27338 Details

References:

  1. Bortolato M, Chen K, Shih JC: Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1527-33. Epub 2008 Jul 4. Pubmed
  2. Kaludercic N, Carpi A, Menabo R, Di Lisa F, Paolocci N: Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim Biophys Acta. 2011 Jul;1813(7):1323-32. Epub 2010 Sep 24. Pubmed

3. Catechol O-methyltransferase

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Catechol O-methyltransferase P21964 Details

References:

  1. Ittiwut R, Listman JB, Ittiwut C, Cubells JF, Weiss RD, Brady K, Oslin D, Farrer LA, Kranzler HR, Gelernter J: Association between polymorphisms in catechol-O-methyltransferase (COMT) and cocaine-induced paranoia in European-American and African-American populations. Am J Med Genet B Neuropsychiatr Genet. 2011 Sep;156(6):651-60. doi: 10.1002/ajmg.b.31205. Epub 2011 Jun 8. Pubmed
  2. Boot E, Booij J, Abeling N, Meijer J, da Silva Alves F, Zinkstok J, Baas F, Linszen D, van Amelsvoort T: Dopamine metabolism in adults with 22q11 deletion syndrome, with and without schizophrenia – relationship with COMT Val108/158 Met polymorphism, gender and symptomatology. J Psychopharmacol. 2011 Jul;25(7):888-95. Epub 2011 Mar 29. Pubmed
  3. Volavka J, Bilder R, Nolan K: Catecholamines and aggression: the role of COMT and MAO polymorphisms. Ann N Y Acad Sci. 2004 Dec;1036:393-8. Pubmed

4. Dopamine beta-hydroxylase

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Dopamine beta-hydroxylase P09172 Details

References:

  1. Goldman JM, Cooper RL, Murr AS: Reproductive functions and hypothalamic catecholamines in response to the soil fumigant metam sodium: adaptations to extended exposures. Neurotoxicol Teratol. 2007 May-Jun;29(3):368-76. Epub 2006 Dec 6. Pubmed
  2. Arboleda G, Huang TJ, Waters C, Verkhratsky A, Fernyhough P, Gibson RM: Insulin-like growth factor-1-dependent maintenance of neuronal metabolism through the phosphatidylinositol 3-kinase-Akt pathway is inhibited by C2-ceramide in CAD cells. Eur J Neurosci. 2007 May;25(10):3030-8. Pubmed
  3. Garland EM, Black BK, Harris PA, Robertson D: Dopamine-beta-hydroxylase in postural tachycardia syndrome. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H684-90. Pubmed
  4. Pyatskowit JW, Prohaska JR: Rodent brain and heart catecholamine levels are altered by different models of copper deficiency. Comp Biochem Physiol C Toxicol Pharmacol. 2007 Mar;145(2):275-81. Epub 2007 Jan 12. Pubmed
  5. LeBlanc J, Ducharme MB: Plasma dopamine and noradrenaline variations in response to stress. Physiol Behav. 2007 Jun 8;91(2-3):208-11. Epub 2007 Mar 2. Pubmed

5. Cytochrome P450 1A2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

6. Cytochrome P450 2C19

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

7. Cytochrome P450 2C9

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

8. Cytochrome P450 2D6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Transporters

1. Solute carrier family 22 member 2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 2 O15244 Details

References:

  1. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K: cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10. Pubmed
  2. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. Pubmed
  3. Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. Pubmed
  4. Busch AE, Karbach U, Miska D, Gorboulev V, Akhoundova A, Volk C, Arndt P, Ulzheimer JC, Sonders MS, Baumann C, Waldegger S, Lang F, Koepsell H: Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol. 1998 Aug;54(2):342-52. Pubmed
  5. Grundemann D, Koster S, Kiefer N, Breidert T, Engelhardt M, Spitzenberger F, Obermuller N, Schomig E: Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biol Chem. 1998 Nov 20;273(47):30915-20. Pubmed
  6. Verhaagh S, Schweifer N, Barlow DP, Zwart R: Cloning of the mouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27. Genomics. 1999 Jan 15;55(2):209-18. Pubmed
  7. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E: Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10. Pubmed

2. Solute carrier family 22 member 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 1 O15245 Details

References:

  1. Bednarczyk D, Ekins S, Wikel JH, Wright SH: Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98. Pubmed
  2. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. Pubmed
  3. Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. Pubmed
  4. Busch AE, Quester S, Ulzheimer JC, Gorboulev V, Akhoundova A, Waldegger S, Lang F, Koepsell H: Monoamine neurotransmitter transport mediated by the polyspecific cation transporter rOCT1. FEBS Lett. 1996 Oct 21;395(2-3):153-6. Pubmed
  5. Breidert T, Spitzenberger F, Grundemann D, Schomig E: Catecholamine transport by the organic cation transporter type 1 (OCT1). Br J Pharmacol. 1998 Sep;125(1):218-24. Pubmed

3. Solute carrier family 22 member 3

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 3 O75751 Details

References:

  1. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. Pubmed

4. Solute carrier family 22 member 5

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 5 O76082 Details

References:

  1. Ohashi R, Tamai I, Nezu Ji J, Nikaido H, Hashimoto N, Oku A, Sai Y, Shimane M, Tsuji A: Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol. 2001 Feb;59(2):358-66. Pubmed
  2. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V: Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther. 1999 Sep;290(3):1482-92. Pubmed

5. POU domain, class 5, transcription factor 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
POU domain, class 5, transcription factor 1 Q01860 Details

References:

  1. Zhu HJ, Appel DI, Grundemann D, Markowitz JS: Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem. 2010 Jul;114(1):142-9. Epub 2010 Apr 6. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:12